Exchange: NASDAQ·Updated 07:30 PM EDT

About RTSN

About

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Retension Pharmaceuticals Inc.?
What is the 52-week high for Retension Pharmaceuticals Inc.?
What is the 52-week low for Retension Pharmaceuticals Inc.?
What is Retension Pharmaceuticals Inc. stock price today?
What was Retension Pharmaceuticals Inc. stock price yesterday?
What is the Price-to-Book ratio of Retension Pharmaceuticals Inc.?
What is the 50-day moving average of Retension Pharmaceuticals Inc.?

Advertisement|Remove ads.